Kornimate/medical-research-clean huggingface dataset:
reveal study: vessel healing after angioplasty

Conditions: Coronary Artery Disease

Summary: to address early vessel healing and thrombus formation after deployment of three distinct groups of stents

a prospective, randomized study providing new evidences on early vessel healing and thrombus development after stenting with different devices.

Eligibility criteria:
inclusion criteria: * lesion length ≤ 20 mm * two significant short lesions exclusion criteria: * life expectancy \< 1 year * left ventricular ejection fraction (lvef) \<30% * chronic kidney disease

Keywords: coronary stent
head-study optimizing the treatment of children with bects

Conditions: Epilepsy, Rolandic

Summary: the investigators hypothesize that levetiracetam is as effective as sulthiame in the treatment of children with bects. patients entering the head-studie are either treated with leveitracetam or sulthiame over a 6 months period. patients are equally randomised to one of the two treatment regimens. administration of medication as blinded capsules.


Eligibility criteria:
inclusion criteria: 1. age between 6 and 12 years 2. weight between 15 kg and 60 kg 3. at least two preceding seizures within the last six months before study start 4. typical electroencephalogram (eeg) with rolando focus (centrotemporal spike or sharp-wave-focus) 5. diagnosis of bects 6. written informed consent from parents and child exclusion criteria: 1. other forms of epilepsy (e.g. continuous spikes and waves during slow sleep \[csws\], landau-kleffner-syndrome) 2. preceding treatment with antiepileptic drugs 3. mental retardation (intelligence quotient \[iq\] \<85) 4. focal neurological deficit 5. relevant major internistic disease (e.g. hepatopathy, nephropathy, endocrinopathy) 6. participation in another clinical trial within the last 30 days

Keywords: benign epilepsy pediatrics children rolandic epilepsy levetiracetam sulthiame
health coaching for patients with cardiovascular disease

Conditions: Congestive Heart Failure Treated; Myocardial Infarction (MI); Coronary Artery Disease; Congestive Heart Failure Chronic

Summary: for patients discharged with a diagnosis of cardiovascular disease coronary artery disease resulting in myocardial infarction and/or congestive heart failure, this study will evaluate if the addition of 12 virtual health coaching sessions over the course of 16 weeks will improve physiological, psychological, and social health outcomes, prove acceptable and satisfactory for these patients with cvd, decrease cvd-related questions and concerns sent to the provider via mychart, and reduce hospital readmission rates over a 90-day period as compared to patients discharged with the same diagnosis who receive standard post-discharge care. the study will also evaluate the perceptions of physician and advanced practice providers related to the health coach as part of the interprofessional team and the amount of time spent addressing cvd-related patient questions and concerns via mychart messages.

the purpose of this mixed methods study is to evaluate the impact of 12 virtual health coaching sessions, provided post-discharge, over the course of 16 weeks on: 1) patient physiological measure of weight; 2) patient-reported perceived stress and medication adherence, and physical, emotional, and social lifestyle behaviors; and 3) mychart messaging to their providers related to concerns and/or questions about their cardiovascular diagnosis. the study will also assess: 4) patient acceptability and satisfaction with the health coaching intervention; 5) acceptability and satisfaction value and/or importance of the health coach intervention and feasibility of integrating the health coach into the inter-professional care team from the provider perspective; impact of the health coaching intervention on provider time spent on addressing mychart messages; and 6) 30-, 60-, and 90-day hospital readmission rates.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * diagnosis of coronary artery disease resulting in myocardial infarction and/or congestive heart failure * physical condition effectively managed by routine healthcare and not requiring urgent medical attention * ability to communicate in english * access to a working phone or computer and ability to communicate via phone or computer. exclusion criteria: * documented cognitive and/or major psychiatric disorders, including dementia, and major depression or anxiety uncontrolled by anti-psychotic and/or anti- depressant medication, and/or admission to a psychiatric facility within the past three months * current alcohol or drug dependency * resident of extended care/skilled facility * prisoners or ward of state.

Keywords: health coaching coronary artery disease congestive heart failure myocardial infarction
optimization of crt using an ecg vest

Conditions: Heart Failure

Summary: despite advancements in implant technology and various techniques of optimization, there is still around 30% non-responder rate to cardiac resynchronization therapy (crt). this study will assess the potential benefit of a body surface mapping technology to optimize crt devices in the chronic sub-optimal responder setting.

cardiac resynchronization therapy (crt) is one of the most important advances in the treatment of patients with heart failure (hf). this therapy, also known as biventricular pacing, utilizes pacemaker leads to synchronize the contraction of the walls within the left ventricle (lv) and the contraction of the left and right ventricles. many randomized trials have conclusively demonstrated that crt improves symptoms, lv structure and function, hospitalization rates, and survival in appropriately selected hf patients. nonetheless, approximately 30% of crt patients will be "non-responders" because they will not demonstrate the expected clinical and/or echocardiographic improvement following therapy. a critical component of assessing crt efficacy during the optimization clinic will be the use of a novel method of body surface electrocardiographic mapping under development by medtronic, called the ecg vest. in this proposal, we describe a research study to assess the potential benefit of using the ecg vest as part of a crt optimization strategy on clinical and echocardiographic outcomes (heart size and function) of patients receiving standard clinical care in the uhvc crt optimization clinic.

Eligibility criteria:
inclusion criteria: * patients (or their legal guardian) must be willing to provide informed consent and a data privacy (hippa) authorization * patient is or will be followed clinically in the uhvc crt optimization clinic * patient has been implanted with a crt device for at least 6 months * patient received an echocardiogram prior to crt implant * patients must be ≥ 18 years of age exclusion criteria: * patient's ef is currently ≥ 50% * patients who are pregnant * patient has unhealed / open wounds on the torso and/or has a history of severe allergic reactions from ecg gel / electrode glue
short-term changes on c-reactive protein (crp) levels after non-surgical periodontal treatment

Conditions: Chronic Periodontitis; Atherosclerotic Cardiovascular Disease

Summary: the hypotheses tested were that levels of c-reactive protein (crp) would be higher in patients with chronic periodontitis in comparison with those without periodontal disease and that the non-surgical periodontal treatment would decrease levels of crp in patients with chronic periodontitis.


Eligibility criteria:
inclusion criteria: patients should have ≥ 20 teeth present; (ii) absence of oral soft tissue lesions; (iii) have ≤ 3 carious lesions in all teeth. in addition, to be included in the test group the subject had to present chronic periodontitis (involvement of at least 5 teeth with at least one site presenting probing depth (pd) ≥ 5 mm and clinical attachment loss (cal) ≥ 3 mm) while to be included in the control group the patient had to exhibit periodontal healthy (bleeding on probing (bop) \ 4mm associated with bop). exclusion criteria: (i) periodontal disease treatment in the previous six months; (ii) aged less than 35 years; (iii) systemic conditions such as history of cvd or any other chronic or immunologic diseases and the use of related drugs in the previous six months; (iv) smokers or former smokers; (v) pregnant or lactating women; (vi) hypertension (\>140 systolic and \> 90 diastolic mmhg); (vii) obesity (body mass index (bmi) ≥ 30 kg/m²); (viii) levels of hdl-cholesterol \> 35.0 mg/dl (ix) levels of ldl-cholesterol \< 160.0 mg/dl (x)levels of triglycerides \< 400.0 mg/dl and (xi) levels of glucose levels \< 100 mg/dl.

Keywords: c-reactive protein risk
cardiovascular effects on growth hormone therapy in adults with growth hormone deficiency

Conditions: Growth Hormone Disorder; Adult Growth Hormone Deficiency

Summary: this trial is conducted in europe. the aim of this trial is to investigate the effect of growth hormone on left ventricle morphology and function (systolic and diastolic).


Eligibility criteria:
inclusion criteria: * adult growth hormone deficiency * at least 2 years without growth hormone treatment exclusion criteria: * supine blood pressure above 160 mmhg systolic or above 100 mmhg diastolic * pregnancy
a study to evaluate the safety and effectiveness of wf10 given to patients with late-stage hiv disease

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give wf10 to adults with late-stage hiv disease. wf10 is suspected to help the immune system fight infection and slow hiv disease progression.

patients are randomized to 1 of 2 treatment groups to receive 4 iv treatment cycles of either wf10 or control (physiological saline solution). patients are monitored throughout the study for: a) clinical progression; b) number, duration, and cause of hospitalizations; c) quality of life; and d) density of cd38 antigen on cd8+ t cells. patients receive treatment for 11 weeks but will continue to be followed for a maximum of 96 weeks. during the follow-up period, patients are evaluated initially at week 18, then at weeks 24, 36, and 48. if the study is continued beyond week 48, follow-up visits are conducted at weeks 72 and 96.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * are hiv-positive. * have a cd4 cell count of less than 50 cells/mm3 within 14 days prior to study entry. * are at least 18 years old. * have received anti-hiv drugs at some time in the past. * agree to practice abstinence or use effective methods of birth control, including the pill, during the study. exclusion criteria patients will not be eligible for this study if they: * are being treated for any form of cancer within 30 days of study entry. * have ever received an hiv vaccine. * have received steroids within 30 days prior to study entry. (note: testosterone is allowed.) * have received certain medications, including anti-hiv treatments that are not approved by the fda. * have participated in another wf10 study. * have an illness or any condition that might exclude them from this study. * are pregnant or breast-feeding. * abuse drugs or medications. * received a blood transfusion within 45 days prior to study entry.

Keywords: placebos infusions, intravenous quality of life anti-hiv agents tetrachlorodecaoxide
strength or power training for patellofemoral pain

Conditions: Patellofemoral Pain

Summary: the objective of this study is to compare a novel 6-week strength training rehabilitation incorporating power exercises (stripe) program to a standard of care (soc) program on short-term and long-term pain, subjective function, patellofemoral pain recurrence rates, and secondary outcomes (hip abduction and extension rate of torque development and single-leg squat kinematics). we hypothesize that participants with patellofemoral pain who complete the stripe program will have 1) decreased pain, 2) improved subjective function, 3) reduced patellofemoral pain recurrence rates, 4a) improved hip abduction/extension rate of torque development, and 4b) decreased hip adduction and pelvic drop during a single leg squat compared to participants who complete a soc rehabilitation program.

the proposed study will compare strength-based exercises, which is the standard of care (soc), that target the hip abductors, hip extensors, lumbo-pelvic, and quadriceps muscles, to a strength training program that utilized power-based exercises (strength training rehabilitation incorporating power exercises \[stripe\]). individuals with patellofemoral pain, both within the military and general population, present with long-term pain, decreased subjective function, and high recurrence rates. our primary outcomes are to determine intervention success with self-reported knee pain, measured by the visual analog scale, subjective function, measured by the anterior knee pain scale, and recurrence rates. recent evidence suggests that two in every three individuals with patellofemoral pain report symptoms up to two years after seeking care, therefore we will assess patellofemoral pain recurrence rates for two years. additionally, the proposed interventions target gluteal muscle function, supporting our selection of secondary outcome variables. we will assess rate of torque development, as power-based exercises are recommended to improve muscle capacity, of both the targeted gluteus medius and gluteus maximus. we will also assess frontal plane kinematics, as the gluteal muscles are responsible for controlling pelvic and hip motion during functional tasks.

Eligibility criteria:
inclusion criteria: * participants to be between the ages of 18-40 years old. * insidious onset of symptoms greater than 3 months. * worst pain in the previous month of 3/10 with two of the following tasks: prolonged sitting, jumping, squatting, kneeling, running, and stair ambulation. exclusion criteria: * other forms of anterior knee pain (osgood-schlatter, tendon pain, bursitis, etc.). * history of lower extremity surgery. * history of patella subluxation, meniscal injury or ligamentous instability. * history of referred pain from the lumbar spine.
efficacy study of fes controlled by electromyographic signal for the treatment of upper limb in post-stroke patients

Conditions: Stroke

Summary: goal of the present study is to evaluate the efficacy of myoelectrically-controlled functional electrical stimulation (mecfes) for the rehabilitation of upper limb in post-stroke patients. mecfes-assisted rehabilitation will be compared with usual care rehabilitation of upper limb. it is hypothesized that that applying mecfes in rehabilitation to assist normal arm movements during rehabilitation of the upper limb in persons with stroke will improve the movement quality and success and thus induce recovery at the body functions level (impairment) and the activity level (disability) of the international classification of function (icf) superior to that induced by usual care rehabilitation.


Eligibility criteria:
inclusion criteria: * hemiplegia/hemiparesis due to a first ischemic or haemorrhagic stroke * at least 1 month post-stroke * willingness to participate the project * minimum voluntary muscle activation of shoulder flexors (\>1 manual muscle test) * passive range of motion (rom) of the shoulder and elbow of more than 90° exclusion criteria: * epilepsy * severe spasticity at upper limb (\>= 3 ashworth scale) * implanted electronic device * respiratory insufficiency * pregnancy * peripheral neuropathies * cutaneous ulcers at the stimulation zone * other use of fes on the upper limb

Keywords: functional electrical stimulation cerebrovascular accident stroke electromyography
day case laparoscopic sacrocolpopexy, a new management

Conditions: Pelvic Organ Prolapse

Summary: facing the stakes of hospital beds, this study assessed day case variant technic of laparoscopic sacrocolpopexy with or without robotic assistant.

pelvic organ prolapse (pop) is an increasingly common functional disorder which affects approximately 40% of female population. of these 12% are symptomatic and suffer of physical and emotional distress. 11% will undergo a surgical procedure. since its introduction by lane in 1982, sacrocolpopexy (scp) became the surgical "gold standard" for correcting vaginal vault . with minimal invasive approach, scp had an mean hospitalization time of 3 to 7 days . with rising health care cost and its inherent economic burden, safe and viable options to reduce cost must be sought. day case surgery has developed rapidly in the usa since the 1970s, and has spread to europe, especially in great britain. but the high authority of health in france found a delay in its development. in view of the evolution of surgical and anesthetic techniques, and the low complication rate of scp, it seemed natural to imagine that this intervention could be done in an ambulatory setting.

Eligibility criteria:
inclusion criteria: * patients with symptomatic anterior, apical and/or posterior compartment prolapse * patients with stage 2 or greater, according to the pop-q classification * patients with a body mass index (bmi) \< 30 * patients with an american society of anesthesiologist (asa) score \< ou = 3. exclusion criteria: * patient with prior history of pelvic cancer surgery and radiotherapy of the pelvis

Keywords: sacrocolpopexy day case surgery laparoscopic
clinical outcome of advanced renal cell carcinoma in taiwan

Conditions: Renal Cell Carcinoma

Summary: the clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied. this study will retrospectively analyse the clinical outcome of advanced renal cell carcinoma captured in taiwan national health insurance research database.

targeted therapy agents have significantly changed the clinical outcome of advanced / metastatic renal cell carcinoma. however, the dosing pattern varied and might result in impact to duration of treatment. in taiwan, national health insurance system has a coverage more than 90% of population and thus can serve as an appropriate database for further analysis on taiwanese advanced renal cell carcinoma. this study will retrospectively analyse the clinical outcome of advanced renal cell carcinoma captured in taiwan national health insurance research database.

Eligibility criteria:
inclusion criteria: * advanced/metastatic renal cell carcinoma exclusion criteria: * n/a

Keywords: renal cell carcinoma sunitinib, pazopanib temsirolimus sorafenib everolimus interferon alpha interleukin 2
study comparing orteronel plus prednisone in participants with chemotherapy-naive metastatic castration-resistant prostate cancer

Conditions: Prostate Cancer

Summary: this is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (tak-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mcrpc)


Eligibility criteria:
inclusion criteria: each patient must meet all of the following inclusion criteria: * voluntary written consent * male patients 18 years or older * histologically or cytologically confirmed diagnosis of prostate adenocarcinoma * radiograph-documented metastatic disease * progressive disease * prior surgical castration or concurrent use of an agent for medical castration * either absence of pain or pain not requiring use of any opioid or narcotic analgesia in the 2 weeks prior to study entry * eastern cooperative oncology group (ecog) performance status 0 or 1 * even if surgically sterilized, patients must practice effective barrier contraception during the entire study treatment and for 4 months after the last dose of study drug, or abstain from heterosexual intercourse * meet screening laboratory values as specified in protocol * stable medical condition exclusion criteria: patients meeting any of the following exclusion criteria are not to be enrolled in the study: * known hypersensitivity to orteronel, prednisone or gonadotropin-releasing hormone (gnrh) analogue * received prior therapy with orteronel, aminoglutethimide, ketoconazole or abiraterone * received antiandrogen therapy within 6 weeks for bicalutamide and 4 weeks for all others prior to first dose of study drug * continuous daily use of oral prednisone or oral dexamethasone for more than 14 days within 3 months prior to study * received prior chemotherapy for prostate cancer with exception of neoadjuvant/adjuvant therapy as part of initial primary treatment for local disease that was completed 2 or more years prior to screening * exposure to radioisotope therapy within 4 weeks of receiving first dose of study drug; exposure to external beam radiation within 2 weeks of start of screening until receiving the first dose of study drug * documented central nervous system metastases * treatment with any investigational compound within 30 days prior to first dose of study drug * current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction * diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected * uncontrolled cardiovascular condition as specified in study protocol * known history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c * unwilling or unable to comply with protocol * uncontrolled nausea, vomiting or diarrhea * known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of orteronel
observational cross-reactivity study for colorectal cancer diagnosis

Conditions: Colorectal Cancer

Summary: the objective of this observational study is to evaluate the false positive rate of the blood test based on molecular biomarkers and risk factors. a total of 250 patients diagnosed with various cancers and gastrointestinal diseases will be enrolled. the main question to be answered is does the blood test have a low false positive rate in the main study population? participants will donate a blood sample as part of their regular medical care for cancer diagnosis and give the consent to know their clinical risk factors.


Eligibility criteria:
inclusion criteria: * patients older than 18 years of age at the time of blood sample collection. * subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form. * patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease. exclusion criteria: * patients who have received previous chemotherapy or radiotherapy. * in case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor. * patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or lynch syndrome. * patients without appropriate staging or diagnosis. * patients with hemolyzed plasma.